checkAd

     165  0 Kommentare Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) - Seite 3

    Lesen Sie auch


    Business Wire (engl.)
    0 Follower
    Autor folgen

    Weitere Artikel des Autors

    Seite 3 von 3

    Silence Therapeutics Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a) - Seite 3 Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced additional …